Business
GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that it has entered into a collaboration agreement with Nippon Kayaku Co., Ltd. ("Nippon Kayaku") to advance GNX201-ADC, a next-generation antibody-drug conjugate (ADC) candidate for the treatment of solid tumors. Under the agreement, the two companies will jointly support preclinical development activities for GNX201-
About this update from Glyconex, Inc.
[{"type":"text","content":"Partnership supports development of tumor-activated glycan-directed ADC designed to improve tumor selectivity","length":109,"tagName":"p"},{"type":"text","content":"NEW TAIPEI CITY, Taiwan, March 23, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that it has entered into a collaboration agreement with Nippon Kayaku Co., Ltd. ("Nippon Kayaku") to advance GNX201-ADC, a next-generation antibody-drug conjugate (ADC) candidate for the treatment of solid tumors. Under the agreement, the two companies will jointly support preclinical development activities for GNX201-ADC, leveraging their respective expertise in antibody engineering and oncology drug development.","length":663,"tagName":"p"},{"type":"image","alt":"GlycoNex, Inc. (PRNewsfoto/GlycoNex, Inc.)","displaySize":"","headline":null,"caption":"GlycoNex, Inc. (PRNewsfoto/GlycoNex, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":377,"url":"https://media.zenfs.com/en/prnewswire.com/72f55fbc984af5a9b79660de98aaf4d4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8XMKVdEFZLutQPcAZKhfTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY2NA--/https://media.zenfs.com/en/prnewswire.com/72f55fbc984af5a9b79660de98aaf4d4","width":400,"height":377}},"href":"https://mma.prnewswire.com/media/2420764/GlycoNex_Inc.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The collaboration will center on research and development activities for GNX201-ADC including optimization of the ADC construct and generation of preclinical data to support regulatory submissions. GNX201-ADC is designed as a protease-activated ADC that remains stable in circulation and is selectively activated in the tumor microenvironment, enabling targeted delivery of its cytotoxic payload while minimizing effects on normal tissues. This differentiated pro-antibody activation strategy is intended to improve therapeutic index and reduce on-target toxicity compared with conventional ADC approaches. Initial development efforts will focus on solid tumors characterized by high levels of glycan antigens.","length":710,"tagName":"p"},{"type":"text","content":""GlycoNex has long been dedicated to advancing anti-glycan an...